BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory (Banas & Rains, 2010, p. 285). Recent research has studied the presence and function of word-of-mouth communication, or post-inoculation talk (see Compton & Pfau, 2009), following exposure to inoculation messages (e.g., Ivanov et al., 2015). Delay is the next element that is necessary in the inoculation process. There has been much debate on whether there is a certain amount of time necessary between inoculation and further attacks on a persons' attitude that will be most effective in strengthening that person's attitude. McGuire (1961) suggested that delay was necessary strengthening a person's attitude and since then many scholars have found evidence